Biotechnology
The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journalNature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for th...
2025-04-06 10:12
3594
Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition
Jasmine Eyal, Age 16, of Singapore, Receives Top Honors and $400,000 in Education Prizes for her Original Video Explaining Mechanogenetic Cellular Engineering LOS ANGELES, April 6, 2025 /PRNewswire/ -- The Breakthrough Prize Foundation today announcedSingapore-based Jasmine Eyal as winner of the...
2025-04-06 06:30
3502
BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS
"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA Editing Exploration of Nature at Shortest Distances Proof of Geometric Langlands Conjecture Special Prize Awarded to Giant of Theoretical Physics Breakthrou...
2025-04-06 06:30
2813
I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S.
– Age-Reversed Stem Cell Technology Now Available to the Public –
PALO ALTO, Calif., April 5, 2025 /PRNewswire/ -- I Peace, Inc. (
https://ipeace.com/en/
2025-04-05 20:00
3144
Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation
BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co.,
Ltd.
2025-04-04 20:58
4828
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund")...
2025-04-03 19:30
6495
Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth
BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary ofChina's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been certified as a 2024 National High-Tech Enterprise, sol...
2025-04-03 15:25
4297
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identific...
2025-04-03 07:45
4902
TCI Biotech Expands US Glass Bottling Capabilities for Liquid Nutraceuticals Innovation
TAIPEI, April 2, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling solution for liquid supplements, positioning it as a cornerstone of its expanded CDMO+ services. Designed...
2025-04-03 00:00
3651
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with...
2025-04-02 22:00
3245
Change in Management: Exyte announces Katrien Verlinden as new President of its Global Business Unit Advanced Technology Facilities
* Katrien Verlinden will take over as President of Exyte's Global Business Unit Advanced Technology Facilities (ATF) effectiveApril 14, 2025 * Verlinden joins from Saipem America Inc., where she served as President and CEO, bringing more than 25 years of international leadership experience *...
2025-04-02 17:00
3082
Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma CSR Highlights * CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. * Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). * Tolerability & Disease Control Rate: Sho...
2025-04-02 15:56
2801
Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug A...
2025-04-01 22:00
3082
Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products
SUZHOU, China, April 1, 2025 /PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high molecular weig...
2025-04-01 20:00
3444
Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidatesDZD8586 and DZD6008, have been selected for pr...
2025-04-01 18:18
2792
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics...
2025-03-31 21:00
2541
Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients
SINGAPORE, March 31, 2025 /PRNewswire/ -- Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the prel...
2025-03-31 18:00
2538
Revenue Soars 44%, Basecare Medical (2170.HK) Advances Toward Global Intelligent Manufacturing
SUZHOU, China, March 31, 2025 /PRNewswire/ -- Amid frequent pro-fertility policy updates, Basecare Medical, a pioneer in the assisted reproductive IVD sector with full fertility health industry chain coverage, released its stellar 2024 performance report. The company achieved annual revenue of ne...
2025-03-31 17:01
4657
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Key Highlights: * Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). * ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS H...
2025-03-31 02:32
3713
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
* Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT * 48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the a...
2025-03-30 19:10
4980
Week's Top Stories
Most Reposted
MTR Lab and ZGC Science City Ltd Establish Ecosystem Partnership
[Picked up by 310 media titles]
2026-03-18 12:00
HOY Unveils a Powerhouse Line-up of Talent for its Bold New Chapter
[Picked up by 301 media titles]
2026-03-20 09:36
Nature's Capital: Why Asia's Governments Are Turning to Nature-Based Solutions
[Picked up by 301 media titles]
2026-03-17 08:00Beijing InfoComm China 2026 Conference Lineup Presents Future of AI in Tech Aligning with the Nation's Next Strategic Five-Year Plan
[Picked up by 296 media titles]
2026-03-18 08:00
Agoda and Gangwon State Join Hands to Elevate Gangwon into a Premier Global Travel Destination
[Picked up by 293 media titles]
2026-03-17 11:29
Most Read
HTCO Launches U.S. Strategic Initiative Led by Chairman Christopher Nixon Cox, Establishes Independent Governance Committee for U.S. Operations
2026-03-13 21:30
7566
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
2026-03-13 21:59
7104
